The Guardian: Antibiotic price drop could stop millions from developing tuberculosis
“The price of a drug crucial to prevent tuberculosis is to be slashed by two-thirds in a deal that could stop millions from developing the disease. … Access to the antibiotic, rifapentine, would stop this ‘latent’ TB from becoming active. … The price drop, negotiated on a volume basis by Unitaid, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the pharmaceutical company Sanofi, means the drug can be used in 100 low- and middle-income countries…” (Lamble, 10/31).

Additional coverage of the deal is available from Devex, Health24, and Science.